Notice: Trying to access array offset on value of type int in /home/customer/www/ryseam.com/public_html/templates/yoo_master2/warp/src/Warp/Config/Repository.php on line 243
Dr John Lee Allen: What does the Novartis Biome UK Heart Health Catalyst mean for innovators and investors?
.

Dr John Lee Allen: What does the Novartis Biome UK Heart Health Catalyst mean for innovators and investors?

Dr John Lee Allen: What does the Novartis Biome UK Heart Health Catalyst mean for innovators and investors?

What does the world-first healthtech investor partnership mean for innovators and investors?

RYSE Asset Management, Novartis, Medtronic, and the NHS have come together in a world-first investor partnership with a bold aim to reimagine cardiovascular care.

The aim: To identify and implement solutions that empower patients to improve their heart health and help prevent future heart attacks or strokes through home-based digital solutions.

Challenge: Identifying and scaling innovations for non-invasive lipid testing and at-home blood pressure testing using software as a medical device. Innovations at venture from a research paper to fully formed product or an extension / new evolution of an existing product will be considered.

  • Marie-Andrée Gamache, Novartis UK & Ireland Country President
  • Dr. John Lee Allen, Managing Partner, RYSE Asset Management
  • Bhavesh Barot, UK & Ireland Vice President, Medtronic
  • Chris Chaney, CEO CW+, Chelsea and Westminster Hospital NHS Foundation Trust

We want to scale at-home solutions that are reducing the two biggest cardiovascular risk factors:

  • Blood pressure monitoring
  • Lipid/cholesterol monitoring